News

Published in the November edition of the Drug Information Association’s Therapeutic Innovation & Regulatory Science (TIRS) journal, the results of the analysis support the TransCelerate-proposed methodology for risk-based

Biologic medicines are produced in living cells and the new Tuas facility encompasses multiple technologies to enable greater speed, productivity and flexibility in commercial-scale manufacturing. Built in less

APL-130277 is the Company’s fast-acting, sublingual, thin filmstrip formulation of apomorphine. OFF episodes are a complication of Parkinson’s disease that leave patients rigid and unable to move and

Both the diabetes and CV standards were established in an effort to make clinical research more efficient while continuing to support the scientific nature of the research. The

Recently, the company has also started a multi-centre Phase Ib trial of BGB324, a selective inhibitor of Axl, in AML patients. The two-part trial is primarily designed to

The Omega-3 fish oil will be sold under the name ‘TapouT’ with all revenues flowing directly into Axxess Pharma. Omega-3 fatty acids are some of the most important

Currently, the company is preparing a new drug application (NDA) for MM-398 in the US to treat these patients with metastatic pancreatic cancer. The FDA fast track status

The NDA was based on an international, randomized, multicenter, double-blind, relapse prevention Phase III trial of paliperidone palmitate three-month injection. More than 500 patients were included in the

NHPN-1010 is being developed to treat noise-induced hearing loss (NIHL) and Cisplatin-induced hearing loss (CIHL). The Phase I trial will determine the safety, tolerability and pharmacokinetic (PK) profile